# A Dose-exploration Study of EDP167 in HoFH

> **NCT07489209** · PHASE2 · RECRUITING · sponsor: **Eddingpharm (Zhuhai) Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Homozygous Familial Hypercholesterolemia (HoFH)

## Interventions

- **DRUG:** EDP167

## Key facts

- **NCT ID:** NCT07489209
- **Lead sponsor:** Eddingpharm (Zhuhai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-06
- **Primary completion:** 2026-10-04
- **Final completion:** 2027-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489209, "A Dose-exploration Study of EDP167 in HoFH". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07489209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*